Alto Neuroscience ANRO Business Segments — Other research and development
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Alto Neuroscience in its filing.
Tagged under the XBRL concept us-gaap:OtherResearchAndDevelopmentExpense.
The official record: Alto Neuroscience’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Alto Neuroscience's business segments — other research and development.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Alto Neuroscience's business segments — other research and development?
- Alto Neuroscience (ANRO) reported business segments — other research and development of $1.2M in Q1 2026.
- How has Alto Neuroscience's business segments — other research and development changed year-over-year?
- Alto Neuroscience's business segments — other research and development increased by 6.1% year-over-year, from $1.13M to $1.2M.
- What is the long-term trend for Alto Neuroscience's business segments — other research and development?
- Over 2 years (2023 to 2025), Alto Neuroscience's business segments — other research and development has grown at a 31.0% compound annual growth rate (CAGR), from $4.39M to $7.53M.
- What does business segments — other research and development mean?
- This metric encompasses the non-personnel research and development expenditures, such as clinical trial site costs, contract research organization fees, and laboratory supplies. It represents the direct external investment required to progress the company's pipeline of therapeutic assets through clinical development stages. Tracking these costs provides insight into the capital intensity and progress of the company's drug development programs.